Is There Change Ahead for the Female Infertility Market? Understand Current Treatments, Issues and Emerging Therapies in This In-Depth Report

Research and Markets (http://www.researchandmarkets.com/research/c0a460/womens_health_ser) has announced the addition of Decision Resources, Inc.’s new report “Women’s Health Series: Is There Change Ahead for the Female Infertility Market?” to their offering.

This report, along with the other reports in the Women’s Health Series, includes primary research with thought-leading clinicians. We conducted an in-depth survey with obstetricians/gynecologists who have expertise in treating infertility. In this report, you will find their opinions on current and emerging therapies as well as on treatment approaches to infertility.

Mounting evidence that a growing number of women are choosing to delay childbirth into their mid-to-late thirties highlights a significant opportunity for new and efficacious infertility treatments. Despite the increasing level of need, the treatment of infertility has not changed significantly over the past several decades because drug developers have been put off by the relatively small market, reimbursement concerns, and the efficacy of existing treatment. However, there is room in this market for an agent that can address the infertility issues of the moderately high percentage of women who have failed existing treatments.

Get the Answers You Need to Shape Your Strategy

– It has long been established that fertility in women drops after age 35; however, an increasing number of women are waiting until this age to have children. What are the primary causes of infertility? What are the age ranges most highly affected by infertility, according to surveyed specialists?

– The newest agent for the treatment of infertility was approved in 2007; however, the most commonly prescribed agent is several decades old. What are the prescribing patterns of specialists for the various causes of infertility? What are the overall success rates of infertility treatments? What reimbursement policies are in place for infertility treatments?

– A significant percentage of women who undergo fertility treatments still fail to conceive. What emerging agents are being developed for infertility? What benefits do these agents offer over existing agents? What is the likelihood that these agents will establish a position in the infertility market?

Scope

– Overview of infertility: normal menstrual cycle and fertility, causes of infertility.

– Currently approved treatments for infertility: clomiphene citrate, follicle-stimulating hormones, human menopausal hormones, Schering-Plough’s Ganirelix, Merck Serono’s Ovidrel.

– Medical practice: U.S. specialists surveyed to determine current prescribing patterns for various types of infertility.

– Emerging treatments: a review of the infertility pipeline, including the lead agent, Schering- Plough’s corifollitropin alfa.

– Outlook for the infertility market: current market drivers and constraints, adoption of emerging agents.

– Women’s Health Series: In 2007, the market for women’s reproductive health exceeded $23 billion worldwide. In the Women’s Health Series, we examine three specific markets, focusing on areas of unmet need and the best marketing strategies to ensure adoption of a new agent. We will provide insight from a variety of thought leaders on the current state of disease treatment and their opinions on the most promising agents currently in the pipeline.

Key Topics Covered:

– Overview of Female Infertility

– Causes of Infertility

– Current Therapies for Female Infertility

– Surgical Interventions

– Medical Practice

– Unexplained Infertility

– Emerging Therapies to Treat Female Infertility

– Outlook for the Female Infertility Market

– List of Tables

– List of Figures

Companies Mentioned:

– Bristol-Myers Squibb

– Duramed Research

– Ferring Pharmaceuticals

– Merck Serono

– Organon

– Pantarhei Bioscience

– Preglem Reproductive Medicine

– Sanofi – Aventis

– Schering-Plough

For more information visit http://www.researchandmarkets.com/research/c0a460/womens_health_ser